Intellia’s world-class leadership team includes executives, founders and advisors whose expertise spans CRISPR/Cas9 and broader genome editing technologies; in vivo and ex vivo therapeutic delivery technologies; preclinical and clinical development; product scale-up and manufacturing; cell and molecular biology; intellectual property; finance; and regulatory affairs. Our scientific advisors, who contribute their insights and expertise to our research, include Dr. Jennifer Doudna, who was named by Time magazine as one of the 100 most influential people in the world.

Management Team

The Intellia management team is comprised of accomplished scientists and business executives who are inspired by CRISPR/Cas9’s potential to cure numerous diseases. Its decades of experience and outstanding records of success in all phases of drug development for biotech companies, large international pharmaceutical corporations, and venture capital and investment firms make Intellia well prepared to lead the revolution underway in gene therapy.

View Details

Nessan Bermingham, Ph.D.

Chief Executive Officer, President and Founder

Nessan Bermingham is the entrepreneur and investor whose vision and drive...

View Details

Thomas Barnes, Ph.D.

Senior Vice President, Innovative Sciences & eXtellia

Tom Barnes has led gene discovery groups and biotherapeutic research teams for nearly...

View Details

Graeme Bell

Executive Vice President, Chief Financial Officer

Graeme Bell is a respected financial executive with an extensive international career in the...

View Details

Jennifer King, Ph.D.

Senior Vice President, Business Development

Jennifer King is Intellia’s Senior Vice President for Business Development, where she is responsible for accessing external sources...

View Details

John Leonard, M.D.

Executive Vice President, R&D

After a 30-year career in pharmaceutical R & D, John Leonard left his position as Chief Scientific Officer and...

View Details

David Morrissey, Ph.D.

Senior Vice President, Platform & Delivery Technology

David Morrissey is one of the world’s foremost experts on therapeutic delivery of nucleic...

View Details

José Rivera

Executive Vice President, General Counsel & Operations

José Rivera has more than 20 years of experience managing complex legal...

View Details

Andrew D. Schiermeier, Ph.D.

Senior Vice President, eXtellia

Andrew Schiermeier has spent two decades as an executive in the biotech and pharmaceutical sectors...

View Details

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications

Jennifer Smoter brings more than 20 years’ experience in the global pharmaceutical...

Board Of Directors

Intellia's board of directors is comprised of industry veterans and experienced investors with demonstrated skills in building leading biotechnology companies.

View Details

Nessan Bermingham, Ph.D.

Chief Executive Officer, President and Founder

Nessan Bermingham is the entrepreneur and investor whose vision and drive...

View Details

Perry Karsen

Chairman of the Board

Perry Karsen brings decades of successful executive leadership and...

View Details

Caroline Dorsa

Board Member

With a distinguished 30-year career as a top financial executive, Caroline Dorsa brings strong financial credentials...

View Details

Jean-Francois Formela, M.D.

Partner - Atlas Venture

Jean-François Formela is a partner at Atlas Venture and focuses on...

View Details

Carl L. Gordon, Ph.D., CFA

Partner - OrbiMed Healthcare Fund Management

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global...

View Details

John Leonard, M.D.

Executive Vice President, R&D

After a 30-year career in pharmaceutical R & D, John Leonard left his position as Chief Scientific Officer and...

Founders

To fulfill the promise of CRISPR/Cas9 genome editing therapeutics, Intellia is guided by a renowned group of scientific advisors. Our founding scientific board includes pioneers in CRISPR/Cas9 biology, nucleic acid delivery and clinical translation.

View Details

Rodolphe Barrangou, Ph.D.

Rodolphe Barrangou is an Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina...

View Details

Nessan Bermingham, Ph.D.

Nessan Bermingham is the entrepreneur and investor whose vision and drive made Intellia “one of the top 10 biotech start-ups...

View Details

Jennifer Doudna, Ph.D.

Dr. Doudna is a member of the departments of Molecular and Cell Biology and Chemistry at the University...

View Details

Rachel Haurwitz, Ph.D.

Rachel is the CEO and co-founder of Caribou Biosciences as well as a co-founder...

View Details

Luciano Marraffini, Ph.D.

Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano's...

View Details

Andy May, Ph.D.

Andy May is the Chief Scientific Officer at Caribou Biosciences, where he leads the development...

View Details

Derrick Rossi, Ph.D.

Derrick Rossi is an Associate Professor of Stem Cell and Regenerative Biology at Harvard Medical School...

View Details

Erik Sontheimer, Ph.D.

Erik Sontheimer is a Professor of Molecular Medicine at the University of Massachusetts Medical School, RNA...

Advisors

View Details

Victor Ambros, Ph.D.

Victor Ambros is the Silverman Professor of Natural Science, and co-director...

View Details

Beverly L. Davidson, Ph.D.

Beverly L. Davidson, Arthur V Meigs Chair in Pediatrics, is...

View Details

Mark Davis, Ph.D.

Mark Davis is a Professor of Chemical Engineering at the California Institute of Technology...

View Details

Eric A. Hendrickson, Ph.D.

Eric A. Hendrickson is Division Chair for Molecular Biology, Head of the Genome Engineering Shared Resource and...

View Details

Dimitri Krainc, M.D., Ph.D.

Dimitri Krainc is a Ward Professor of Neurology, Chairman of Department of the Neurology and Director of...

View Details

Arthur Krieg, M.D.

Arthur Krieg has extensive experience developing nucleic acid drugs and is the...